This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Here's Why You Should Hold on to McKesson (MCK) Stock Now
by Zacks Equity Research
McKesson (MCK) continues to benefit from the multi-year strategic growth initiative and strength in the Distribution Solutions segment.
Zacks.com featured highlights include: Abbott Laboratories, Facebook, Stanley Black & Decker, Leidos and Euronet
by Zacks Equity Research
Zacks.com featured highlights include: Abbott Laboratories, Facebook, Stanley Black & Decker, Leidos and Euronet
The Zacks Analyst Blog Highlights: Becton, Dickinson and Co, Abbott, Myomo and Apyx Medical
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Becton, Dickinson and Co, Abbott, Myomo and Apyx Medical
Ecolab (ECL) Q4 Earnings In Line With Estimates, Revenues Lag
by Zacks Equity Research
Although Ecolab's (ECL) fourth-quarter results reflect weakness in the Global Industrial and Institutional segments, its Global Healthcare and Life Sciences unit shows strength.
CVS Health (CVS) Q4 Earnings Top Estimates but Decline Y/Y
by Zacks Equity Research
The pandemic affects CVS Health's (CVS) fourth-quarter revenues in the Pharmacy Services segments as new therapy prescriptions reduce due to lower provider visits.
BD (BDX) Gets EUA, CE Mark for New Molecular Diagnostic Test
by Zacks Equity Research
BD's (BDX) new test has the capability to detect SARS-CoV-2 and Influenza A+B in a single test.
5 Top Ranked Stocks With Solid Sales Growth to Buy Right Now
by Swayta Shah
Sales growth is an important indicator of a company's health and ability to sustain its business. Let's check Abbott (ABT), Facebook (FB), Stanley Black & Decker (SWK), Leidos (LDOS) & Euronet (EEFT) as these might witness solid sales growth.
TeleFlex (TFX) Organic Sales Hit by COVID-19, Urolift Grows
by Zacks Equity Research
TeleFlex (TFX) Interventional business revenues are down due to the cancellation of certain non-emergent procedures.
Intersect ENT's (XENT) SDS With PROPEL Mini Now in U.S.
by Zacks Equity Research
Intersect ENT's (XENT) SDS, packaged with its PROPEL Mini Sinus Implant, is expected to boost the company's business following its U.S. availability.
DaVita (DVA) Q4 Earnings and Revenues Fall Shy of Estimates
by Zacks Equity Research
DaVita's (DVA) bottomline in Q4 declines year over year.
DexCom (DXCM) Q4 Earnings Match Estimates, Revenues Beat
by Zacks Equity Research
DexCom's (DXCM) fourth-quarter results benefit from domestic and international revenue growth.
Zimmer (ZBH) Non-Core Arm Spinoff to Aid Amid COVID-19 Crisis
by Zacks Equity Research
In the Americas, there is increased pressure on Zimmer Biomet (ZBH) procedural volume as a result of surge in infections.
Bio-Rad (BIO) Q4 Earnings Surpass Estimates, Margins Rise
by Zacks Equity Research
Bio-Rad's (BIO) fourth-quarter 2020 results reflect strong performance by the Life Science segment, boosted by coronavirus-led increased testing demand.
Illumina (ILMN) Q4 Earnings Top Estimates, Margins Decline
by Zacks Equity Research
Illumina (ILMN) exhibits dismal performance by the Service & Other segment in the fourth quarter of 2020 due to pandemic-led business disruptions.
Orthofix (OFIX) Launches Limb Lengthening System in US & UK
by Zacks Equity Research
With FITBONE, Orthofix (OFIX) claims itself to be the only orthopedic company that offers a comprehensive portfolio of both internal and external fixation solutions for limb reconstruction.
Pacific Biosciences (PACB) Q4 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Pacific Biosciences (PACB) suffers a Product revenue decline in the fourth quarter.
Why You Should Retain Abiomed (ABMD) Stock in Your Portfolio
by Zacks Equity Research
Investor confidence is high in Abiomed (ABMD) stock, courtesy of its solid prospects.
LabCorp (LH) Q4 Earnings Beat Estimates, Margins Expand
by Zacks Equity Research
LabCorp's (LH) 2021 guidance projects significant downfall in COVID-related testing revenues.
Cerner (CERN) Q4 Earnings Match Estimates, Revenues Beat
by Zacks Equity Research
Cerner's (CERN) fourth-quarter results benefit from gains in Subscriptions and Managed services units, and expansion in gross margin.
HEXO Soars: Stock Adds 7.9% in Session
by Zacks Equity Research
HEXO saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
Here's Why Abbott (ABT) is a Great Momentum Stock to Buy
by Zacks Equity Research
Does Abbott (ABT) have what it takes to be a top stock pick for momentum investors? Let's find out.
Surmodics (SRDX) Q1 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Surmodics (SRDX) records higher revenues in its In Vitro Diagnostics core unit in the fiscal first quarter.
QIAGEN (QGEN) Q4 Earnings Beat Estimates, Margins Improve
by Zacks Equity Research
QIAGEN's (QGEN) high level of sales for product groups used in the COVID-19 pandemic response drove the top line.
Luminex (LMNX) Q4 Earnings Miss Estimates, Revenues Beat
by Zacks Equity Research
Luminex (LMNX) witnesses total sample-to-answer molecular diagnostics revenue growth in the fourth quarter.
Cardiovascular System's (CSII) OAS Cures 1st Patient in Europe
by Zacks Equity Research
Cardiovascular System's (CSII) Diamondback 360 Coronary OAS provides physicians in Europe with an effective treatment option for difficult-to-treat patient population.